Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?
The disabling and painful disease osteoarthritis (OA) is the most common form of arthritis. Strong evidence suggests that a subpopulation of OA patients has a form of OA driven by inflammation. Consequently, understanding when inflammation is the driver of disease progression and which OA patients might benefit from anti-inflammatory treatment is a topic of intense research in the OA field. We have reviewed the current literature on OA, with an emphasis on inflammation in OA, biochemical markers of structural damage, and anti-inflammatory treatments for OA. The literature suggests that the OA patient population is diverse, consisting of several subpopulations, including one associated with inflammation. This inflammatory subpopulation may be identified by a combination of novel serological inflammatory biomarkers. Preliminary evidence from small clinical studies suggests that this subpopulation may benefit from anti-inflammatory treatment currently reserved for other inflammatory arthritides.
a Rheumatology, Biomarkers and Research , Nordic Bioscience , Herlev , Denmark.
A S
AS
Siebuhr
a Rheumatology, Biomarkers and Research , Nordic Bioscience , Herlev , Denmark.
A C
AC
Bay-Jensen
b Thurston Arthritis Research Center , University of North Carolina , NC , USA.
J M
JM
Jordan
a Rheumatology, Biomarkers and Research , Nordic Bioscience , Herlev , Denmark.
C F
CF
Kjelgaard-Petersen
c Centre for Clinical and Basic Research , Ballerup , Denmark.
C
C
Christiansen
d New York University School of Medicine and Hospital for Joint Diseases, NYU Langone Medical Center , New York , NY , USA.
S B
SB
Abramson
d New York University School of Medicine and Hospital for Joint Diseases, NYU Langone Medical Center , New York , NY , USA.
M
M
Attur
e Department of Rheumatology, AP-HP Saint-Antoine Hospital , Sorbonne University , Paris , France.
F
F
Berenbaum
f Department of Medicine and Duke Molecular Physiology Institute , Duke University School of Medicine , Durham , NC , USA.
V
V
Kraus
a Rheumatology, Biomarkers and Research , Nordic Bioscience , Herlev , Denmark.
M A
MA
Karsdal
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002097:C-Reactive Protein / Q000276:immunology; D002358:Cartilage, Articular / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000276:immunology; D008279:Magnetic Resonance Imaging; D010003:Osteoarthritis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D057285:Precision Medicine; D011379:Prognosis; D013583:Synovial Membrane / Q000276:immunology* / Q000473:pathology; D013585:Synovitis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology
D018501:Antirheumatic Agents; D015415:Biomarkers; D002097:C-Reactive Protein